New drug combo for advanced gastrointestinal cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of gastrointestinal cancer (esophageal, gastric, colorectal, or other) that has spread or cannot be removed with surgery.
- You are between 18 and 75 years old.
- Your overall health is good (able to take care of yourself and up and about more than half the day).
- You have not had major heart problems, and your heart function is normal.
- You have not had severe side effects from previous immunotherapy, and you do not have active infections like hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
This trial tests a new drug called BL-B01D1, alone or combined with another drug (SI-B003), for people with cervical or other gynecologic cancers that have spread or come back after standard treatments. The goal is to see if this treatment can help when other options have stopped working.
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial tests a new drug called SI-B036 in people with advanced digestive tract or other solid tumors that have spread. It aims to see if the drug is safe and effective. You may qualify if you have a measurable tumor and are in relatively good health.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.